Primary liver cancer is the sixth most common cancer and the third most common cause of
cancer-related deaths worldwide. Hepatocellular carcinoma (HCC) is a major histologic type …

Solid tumors are composed of a highly complex and heterogenic microenvironment, with
increasing metabolic status. This environment plays a crucial role in the clinical therapeutic …

Hepatocellular carcinoma (HCC) is one of the most common causes of malignancy-related
deaths. Lenvatinib, as a multi-targeted tyrosine kinase inhibitor, has gained increasing …

Abstract Background Hypoxia-inducible factors (HIFs) are the most essential endogenous
transcription factors in the hypoxic microenvironment and regulate multiple genes involved …

Ferroptosis is an important mode of regulated cell death (RCD). Its inhibition is closely
related to therapeutic resistance and poor prognosis in hepatocellular carcinoma (HCC) …

Background Hepatocellular carcinoma (HCC) is one of the most common malignant cancers
in humans and has a high fatality rate. Despite pharmacological advances such as sorafenib …

Lenvatinib is a multi-target tyrosine kinase inhibitor widely used in the treatment of
hepatocellular carcinoma (HCC). Its primary mechanism of action involves inhibiting signal …

Hepatocellular carcinoma (HCC) is a deadly malignancy with limited treatment options. As a
first-line treatment for advanced HCC, Lenvatinib has been applicated in clinic since 2018 …

Hepatocellular cancer (HCC) therapy is in need for an ideal companion diagnostic.
Preclinical experimental studies have identified the insulin receptor (IR) and its synergistic …

The majority of novel targeted anticancer drugs are weakly basic molecules with poor
aqueous solubility which ultimately compromise their oral bioavailability. Lenvatinib (Lnv) is …